On the Record · Amgen
Amgen competitors, on the record
The companies Amgen names as competitors in its annual reports, 2023 to 2025, and the companies that name Amgen, each with the sentence and the filing.
Who Amgen names
| Company | Named in |
|---|---|
| Novartis AG | 2025 |
| Regeneron Pharmaceuticals, Inc. | 2025 |
In its own words
Novartis AG, Regeneron Pharmaceuticals, Inc.
Word for word“Product Territory Competitor-marketed product Competitors Prolia U.S., Europe & Asia Pacific Bisphosphonates, including generics Various U.S., Europe & Asia Pacific Denosumab biosimilars Various Repatha U.S., Europe & Asia Pacific LEQVIO ® Novartis AG U.S., Europe & Asia Pacific PRALUENT ® Regeneron Pharmaceuticals, Inc.” 10-K for 2025
Who names Amgen
Companies whose own annual reports name Amgen as a competitor.
Word for word“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2024
Word for word“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
Word for word“There are also a number of products for the treatment of first and second line SCLC in various phases of development, including Amgen Inc.’s tarlatamab, which was approved for second line use in the U.S. in May 2024.” 10-K for 2025
Read from Amgen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.